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Worldwide 190 million people are severely visually impaired, and about 32 million are blind1. 
In Europe, macular degeneration and glaucoma are considered the leading causes of vision 
loss. Blindness is a widespread global public health issue, representing a significant personal 
and societal burden, limiting educational opportunities, affecting economic possibilities and 
reducing the quality of life2–4. Although various approaches have been attempted so far, 
including drug treatment, gene therapy, stem-cells transplantation, optogenetics, and visual 
prostheses, with encouraging results in animal models and some also in patients5, there is still 
no established method to restore sight. Among those, retinal prostheses succeeded in restoring 
a primitive form of vision6,7, such as locating and recognizing objects. However, fighting 
blindness with retinal prostheses requires challenges not yet achieved: implanting a prosthesis 
(i) large enough to cover the retinal surface and (ii) embedding a high number of highly dense
stimulatory elements. We developed an injectable, self-opening, and freestanding prosthesis
restoring at least 40° of visual field, therefore covering at least a retinal surface of 12 mm in
diameter. Moreover, it has a hemispherical shape in order to minimize the distance from the
targeted cells over its entire surface. It also operates according to a photovoltaic stimulation
principle and it should be injected trough a minimal scleral incision. Our implant is based on
PDMS as shell material, embedding 2345 organic photovoltaic stimulating pixels made of
conjugated polymers (100 µm and 150 µm in diameter, density 54 px/mm2), covering an
active area of 13 mm (44° of visual field). Our results indicate that those pixels can deliver up
to 54 mA/cm2 and generate an electrode potential up to 200 mV when illuminated with a
pulse light of 10 ms, 32 µW/mm2, at 530 nm. Accelerated aging tests and experiments with
explanted retinas are currently under evaluation. These preliminary results show the potential
of organic photovoltaics in the fabrication of a retinal prosthesis with large area and high
stimulation efficiency. The biocompatibility and mechanical compliance of the materials
represent a step forward in building advanced photovoltaic retinal prostheses.
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